We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

SD BIOSENSOR

SD BIOSENSOR develops immunological and molecular diagnostics and blood glucose self-monitoring systems, glycated hem... read more Featured Products: More products

Download Mobile App




Repeatability and Reproducibility of a Handheld Quantitative G6PD Diagnostic

By LabMedica International staff writers
Posted on 03 Mar 2022

Novel treatment regimens for the radical cure of P. More...

vivax malaria are more effective than current options but require prior quantitative G6PD testing. The reference method for quantitative G6PD measurement is spectrophotometry but, due to its operational characteristics, is not suitable for routine use. Furthermore, poor inter-laboratory reproducibility of spectrophotometry has prevented quantitative global definitions of G6PD deficiency. SD Biosensor (ROK) have developed a novel handheld “Biosensor” device (G6PD STANDARD), which measures G6PD activity within two minutes and has operational characteristics suited to point of care diagnosis.

Approximately 400 million people worldwide are affected by glucose-6-phosphate dehydrogenase enzyme deficiency (G6PDd), with allele frequencies reaching up to 35% in malaria endemic areas. The introduction of novel short course treatment regimens for the radical cure of Plasmodium vivax requires reliable point-of-care diagnosis that can identify G6PD deficient individuals.

The G6PD gene is located on the X-chromosome; males are either hemizygous deficient or normal, whereas females are homozygous deficient, normal, or heterozygous for the gene. Heterozygous females have two distinct red blood cell (RBC) populations, G6PD normal and G6PD deficient that circulate in a ratio determined through the random process of lyonization Therefore, the G6PD activity levels of heterozygous females is dependent on the proportion of deficient cells, those cells at greatest risk of drug induced hemolysis.

An international team of medical scientists led by those at the Charles Darwin University (Darwin, Australia) determined the repeatability of a point-of-care assay (precision when repeated under constant conditions) and reproducibility (assay precision under different conditions, such as across devices, operators and sites), since robust performance of these characteristics is necessary for rolling-out universal thresholds for clinical decisions.

A hand-held quantitative G6PD diagnostic developed by SD Biosensor (STANDARD G6PD test, Suwon-si, Republic of Korea), and was tested in the study. The Biosensor device quantifies hemoglobin (Hb) concentration using a photo-reflectance based algorithm informed by the sample’s color intensity. This is measured on a separate spot to that for the G6PD activity. The handheld device displays G6PD activity (in U/gHb) and hemoglobin (Hb) levels (in g/dL) two minutes after applying the blood buffer solution, however the manufacturer indicates that results cannot be considered if Hb readings are equal to or below 7g/dL. To ensure that identical samples were tested across all sites, commercial controls were used with all controls within one phase being from the same lot (Analytical Control Systems, Inc., Fishers, IN; USA). Spectrophotometry was performed using kits from Pointe Scientific (Canton, MI, USA).

The investigators reported that when tested at one site, the mean coefficient of variation (CV) was 0.111, 0.172 and 0.260 for high, intermediate, and low controls across all devices respectively; combined G6PD Biosensor readings correlated well with spectrophotometry (rs = 0.859). When tested in different laboratories, correlation was lower (rs = 0.604) and G6PD activity determined by Biosensor for the low and intermediate controls overlapped. The use of lyophilized human blood samples rather than fresh blood may have affected these findings. Biosensor G6PD readings between sites did not differ significantly, whereas spectrophotometry readings differed markedly between sites.

The authors concluded that their findings suggest that the Biosensor offers reproducible quantitative diagnosis of G6PD status at the point-of-care in the hands of well-trained technicians. If repeatability and reproducibility as well as the previously reported accuracy are confirmed under real life conditions, the Biosensor has the potential to simplify access to effective radical cure of P. vivax malaria. The study was published on February 17, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Charles Darwin University
SD Biosensor 
Analytical Control Systems 
Pointe Scientific 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.